Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Twinlab facility

This article was originally published in The Tan Sheet

Executive Summary

Manufacturing of private label and Bronson catalog products will be shifted internally, outsourced or discontinued in light of firm's plans to close or sell its Tempe, Ariz. plant. Branded products are manufactured at plants in New York, Utah and will not be affected, Twinlab says March 4. Shift from manufacturing at Arizona site, which will be phased in over the next few months, will help "streamline operations, increase productivity" and cost-effectiveness, Twinlab says. Ultimately, 12% of firm's workforce, mostly at production level, will be eliminated by the action...

You may also be interested in...

Twinlab Manufacturing Facility To Be Bought By Anabolic Labs

Anabolic Labs expects its acquisition of Twinlab's Health Factors International manufacturing facility to close by the beginning of May

Rare Disease Advocates Lobby US Congress For FDA Center of Excellence

Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.

FDA’s 2021 Budget Priorities For Cosmetics, Food Programs Include AI Use In Postmarket Oversight

FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts